In the past week, CRBU stock has gone down by -4.16%, with a monthly decline of -22.80% and a quarterly plunge of -39.80%. The volatility ratio for the week is 5.00%, and the volatility levels for the last 30 days are 5.70% for Caribou Biosciences Inc The simple moving average for the last 20 days is -9.86% for CRBU stock, with a simple moving average of -33.65% for the last 200 days.
Is It Worth Investing in Caribou Biosciences Inc (NASDAQ: CRBU) Right Now?
The stock has a 36-month beta value of 2.56. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRBU is 79.62M, and at present, short sellers hold a 14.25% of that float. On May 02, 2024, the average trading volume of CRBU was 1.62M shares.
CRBU) stock’s latest price update
Caribou Biosciences Inc (NASDAQ: CRBU)’s stock price has increased by 1.65 compared to its previous closing price of 3.63. However, the company has seen a -4.16% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-24 that BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.
Analysts’ Opinion of CRBU
Evercore ISI, on the other hand, stated in their research note that they expect to see CRBU reach a price target of $13. The rating they have provided for CRBU stocks is “Outperform” according to the report published on October 31st, 2023.
Truist gave a rating of “Buy” to CRBU, setting the target price at $23 in the report published on July 11th of the previous year.
CRBU Trading at -32.03% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.04% of loss for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 5.00%, as shares sank -21.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.81% lower at present.
During the last 5 trading sessions, CRBU fell by -4.16%, which changed the moving average for the period of 200-days by -41.34% in comparison to the 20-day moving average, which settled at $4.04. In addition, Caribou Biosciences Inc saw -35.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -3.37 for the present operating margin
- 0.82 for the gross margin
The net margin for Caribou Biosciences Inc stands at -2.87. The total capital return value is set at -0.28. Equity return is now at value -30.50, with -24.74 for asset returns.
Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.39. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 37.78.
Currently, EBITDA for the company is -112.53 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 8.98. The receivables turnover for the company is 8.93for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.97.
Conclusion
To sum up, Caribou Biosciences Inc (CRBU) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
